Biopharmaceutical News and Research

RSS

UMass Amherst researchers develop novel strategy to outsmart antibiotic-resistant ‘superbugs’

Antibiotic-resistant "superbugs" that can defeat efforts to kill them are an urgent public health crisis, and according to the Centers for Disease Control, more than 2.8 million antibiotic-resistant infections occur each year.

18 Dec 2023

UVA atlas unveils cellular blueprint of atherosclerosis

University of Virginia School of Medicine researchers have created an "atlas of atherosclerosis" that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes and coronary artery disease.

12 Dec 2023

Research uncovers potential treatment target for rare, genetic type of epilepsy

Researchers at the Francis Crick Institute, UCL and MSD have identified a potential treatment target for a genetic type of epilepsy.

11 Dec 2023

Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

Gyros Protein Technologies AB today announced a partnership with offer Biotage®.

From Gyros Protein Technologies AB 8 Dec 2023

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials-;the third WCNDD therapeutic to reach that benchmark.

7 Dec 2023

Refeyn launches KaritroMP for rapid and reproducible characterization of large viral vectors

Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP.

From Refeyn 4 Dec 2023

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH).

From CN-Bio 4 Dec 2023

UK Biobank unveils world's largest genetic data set

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants.

4 Dec 2023

UK Biobank data opens door to new era of precision medicine

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants.

29 Nov 2023

Novel method can detect contaminants in T-cell cultures within 24 hours

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a novel method capable of identifying contaminants in T-cell cultures within 24 hours.

27 Nov 2023

Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

20 Nov 2023

Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

An interview with Dr Beverley Isherwood.

16 Nov 2023

ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract.

From ATCC 13 Nov 2023

Data, Design, and Discovery: Andrew Buchanan's Impact on Biologics Innovation

Andrew Buchanan on the Future of Biologics and AI

10 Nov 2023

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

7 Nov 2023

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London

7 Nov 2023

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.

6 Nov 2023

The New Picus® 2 sets a new standard for connected electronic pipettes

Sartorius launches new electronic pipette Picus 2.

From Sartorius 16 Oct 2023

Scientists identify nearly a dozen genes responsible for coronary artery calcification

An international team of scientists has identified nearly a dozen genes that contribute to calcium buildup in our coronary arteries that can lead to life-threatening coronary artery disease, a condition responsible for up to one in four deaths in the United States.

11 Oct 2023

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).

9 Oct 2023